Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Long-Term Deferred Tax (2016 - 2025)

Adma Biologics (ADMA) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $74.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax changed N/A year-over-year to $74.4 million, compared with a TTM value of $74.4 million through Sep 2025, changed N/A, and an annual FY2024 reading of $84.3 million, changed N/A over the prior year.
  • Long-Term Deferred Tax was $74.4 million for Q3 2025 at Adma Biologics, down from $79.2 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $84.3 million in Q4 2024 and bottomed at $74.4 million in Q3 2025.